Tokyo, Japan (March 26, 2015) – Following its announcement yesterday regarding the closure of the merger between its subsidiary Ranbaxy Laboratories Limited (“Ranbaxy”) and Sun Pharmaceutical Industries Ltd. (“Sun Pharma”), Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) today made an additional announcement, detailed below.

(1) In accordance with the conclusion of merger between Daiichi Sankyo’s subsidiary Ranbaxy and Sun Pharma, the profit margin from exchange of stocks resulting from the merger will be included as extraordinary profit in a standalone statement of accounts, and the profit margin from subsidiary merger (before tax) will be included in the consolidated results.

(2) The amounts included in the results for March 2015 are as follows.
   A) Standalone statement (J-GAAP)
      Extraordinary profit: 338 billion yen

   B) Consolidated results (IFRS)
      Profit related to discontinued operation: 340 billion yen